CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-20 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B-2 Preferred Stock | −85,065 | 0 | ||
| 2020-10-20 | Versant Venture Capital VI, L.P. 10% owner | Conversion · Series B-2 Preferred Stock | −198,485 | 0 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion | +13,671 | 389,218 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion | +3,394 | 392,612 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion | +1,452 | 394,064 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion · Series A Preferred Stock | −13,671 | 0 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion · Series B-1 Preferred Stock | −3,394 | 0 | ||
| 2020-10-20 | Symons Julian A. See Remarks | Conversion · Series B-2 Preferred Stock | −1,452 | 0 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion | +6,835 | 6,835 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion | +1,697 | 8,532 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion | +726 | 9,258 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion · Series A Preferred Stock | −6,835 | 0 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion · Series B-1 Preferred Stock | −1,697 | 0 | ||
| 2020-10-20 | Quan Lucinda Y. See Remarks | Conversion · Series B-2 Preferred Stock | −726 | 0 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion | +2,145,991 | 2,145,991 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion | +662,799 | 2,808,790 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion | +283,550 | 3,092,340 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion · Series A Preferred Stock | −2,145,991 | 0 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion · Series B-1 Preferred Stock | −662,799 | 0 | ||
| 2020-10-20 | Nuechterlein Carole Director | Conversion · Series B-2 Preferred Stock | −283,550 | 0 |
Page 10 of 12 · 238 trades